Advertisement
Advertisement
U.S. markets open in 45 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Humacyte, Inc. (HUMA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.94-0.12 (-1.08%)
At close: 04:00PM EST
10.07 -0.87 (-7.95%)
After hours: 06:56PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close11.06
Open10.87
Bid10.12 x 1200
Ask10.90 x 900
Day's Range10.00 - 11.00
52 Week Range8.61 - 17.45
Volume408,178
Avg. Volume395,556
Market Cap1.127B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for HUMA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Humacyte, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/29/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021

    -- Patency and host cell remodeling of the HAV were observed in all study implants – -- Preclinical study is one component of Humacyte’s expansion of the testing of the HAV in a broader cardiac bypass surgery application – DURHAM, N.C., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced positive results from a preclinical study of the sm

  • GlobeNewswire

    Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System

    – Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency observed at 12 months post-implantation – – Data presented today in keynote presentation at 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS2021) – Durham, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology plat

  • GlobeNewswire

    Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights

    -- Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds -- -- Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications -- DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial resu

Advertisement
Advertisement